PMEF
CORT icon

Point72 Middle East FZE’s Corcept Therapeutics CORT Stock Holding History

Point72 Middle East FZE’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,602
Closed -$147K – 1517
2023
Q2 		$147K Sell
6,602
-180
-3% -$4.14K ﹤0.01% 1132
2023
Q1 		$147K Buy
6,782
+1,524
+29% +$33.4K 0.01% 1024
2022
Q4 		$107K Buy
+5,258
New +$132K ﹤0.01% 1252

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Point72 Middle East FZE's CORT Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Corcept Therapeutics (CORT) in Q3 2023, closing a stake of 6,602 shares — an estimated $147K sold.

Point72 Middle East FZE first reported a position in CORT in Q4 2022 and held it in 3 quarters. The position peaked at $147K in Q1 2023. 246 funds tracked by Wall St. Rank hold CORT as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Corcept Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 6,602 Corcept Therapeutics shares in Q3 2023, an estimated $147K.
  • Point72 Middle East FZE first reported a position in Corcept Therapeutics in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Corcept Therapeutics position peaked at $147K in Q1 2023.
  • 246 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.